CRISPR Therapeutics AG (CRSP)
47.88
+1.59
(+3.43%)
USD |
NASDAQ |
Nov 22, 16:00
48.00
+0.12
(+0.25%)
After-Hours: 20:00
CRISPR Therapeutics Debt to Equity Ratio
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.00 |
| Date | Value |
|---|---|
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | |
| December 31, 2015 | -1.318 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Dec 2019
--
Maximum
Dec 2019
--
Average
--
Median
Dec 2019
Debt to Equity Ratio Benchmarks
| Vertex Pharmaceuticals Inc | 0.00 |
| AC Immune SA | 0.00 |
| Addex Therapeutics Ltd | 0.00 |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | 0.00 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 2.256B |
| Total Liabilities (Quarterly) | 316.47M |
| Shareholders Equity (Quarterly) | 1.940B |